BACKGROUND: Patients with renal cell carcinoma (RCC) who are black tend to have poorer prognosis than similar patients who are white. This study examined whether the racial disparity in RCC patient survival varies by demographic and clinical characteristics. METHODS: Nearly 40,000 patients (4359 black and 34,991 white) diagnosed with invasive RCC from 1992 to 2007 were identified from 12 registries in the National Cancer Institute Surveillance, Epidemiology, and End Results program, covering approximately 14% of the US population. Relative survival rates through 2008 were computed using the actuarial method. RESULTS: Proportionally more blacks than whites were diagnosed with RCC under age 50 and with localized cancer. Overall, the 5-year relative survival rates were 72.6% (95% confidence interval 72.0%-73.2%) for white and 68.0% (66.2%-69.8%) for black patients. Survival was higher among women than men and among younger than older patients. Survival decreased with advancing tumor stage and, within each stage, decreased with increasing tumor size. Patients with clear cell RCC, a more common form among whites, had poorer prognosis than patients with papillary or chromophobe subtypes, which are more common among blacks. Survival for patients who received no surgical treatment (10.5% of white patients and 14.5% of black patients) was substantially lower than for patients treated with nephrectomy, with similar survival among whites and blacks. In all other demographic and clinical subgroups of patients, whites consistently had a survival advantage over blacks. CONCLUSIONS: Patients with RCC who are white consistently have a survival advantage over those RCC patients who are black, regardless of age, sex, tumor stage or size, histological subtype, or surgical treatment.
BACKGROUND:Patients with renal cell carcinoma (RCC) who are black tend to have poorer prognosis than similar patients who are white. This study examined whether the racial disparity in RCCpatient survival varies by demographic and clinical characteristics. METHODS: Nearly 40,000 patients (4359 black and 34,991 white) diagnosed with invasive RCC from 1992 to 2007 were identified from 12 registries in the National Cancer Institute Surveillance, Epidemiology, and End Results program, covering approximately 14% of the US population. Relative survival rates through 2008 were computed using the actuarial method. RESULTS: Proportionally more blacks than whites were diagnosed with RCC under age 50 and with localized cancer. Overall, the 5-year relative survival rates were 72.6% (95% confidence interval 72.0%-73.2%) for white and 68.0% (66.2%-69.8%) for black patients. Survival was higher among women than men and among younger than older patients. Survival decreased with advancing tumor stage and, within each stage, decreased with increasing tumor size. Patients with clear cell RCC, a more common form among whites, had poorer prognosis than patients with papillary or chromophobe subtypes, which are more common among blacks. Survival for patients who received no surgical treatment (10.5% of white patients and 14.5% of black patients) was substantially lower than for patients treated with nephrectomy, with similar survival among whites and blacks. In all other demographic and clinical subgroups of patients, whites consistently had a survival advantage over blacks. CONCLUSIONS:Patients with RCC who are white consistently have a survival advantage over those RCCpatients who are black, regardless of age, sex, tumor stage or size, histological subtype, or surgical treatment.
Authors: Bradley C Leibovich; Christine M Lohse; Paul L Crispen; Stephen A Boorjian; R Houston Thompson; Michael L Blute; John C Cheville Journal: J Urol Date: 2010-02-19 Impact factor: 7.450
Authors: Lawrence J Appel; Jackson T Wright; Tom Greene; Lawrence Y Agodoa; Brad C Astor; George L Bakris; William H Cleveland; Jeanne Charleston; Gabriel Contreras; Marquetta L Faulkner; Francis B Gabbai; Jennifer J Gassman; Lee A Hebert; Kenneth A Jamerson; Joel D Kopple; John W Kusek; James P Lash; Janice P Lea; Julia B Lewis; Michael S Lipkowitz; Shaul G Massry; Edgar R Miller; Keith Norris; Robert A Phillips; Velvie A Pogue; Otelio S Randall; Stephen G Rostand; Miroslaw J Smogorzewski; Robert D Toto; Xuelei Wang Journal: N Engl J Med Date: 2010-09-02 Impact factor: 91.245
Authors: Anbesaw Selassie; C Shaun Wagner; Marilyn L Laken; M LaFrance Ferguson; Keith C Ferdinand; Brent M Egan Journal: Hypertension Date: 2011-09-12 Impact factor: 10.190
Authors: Alexander Sankin; Jacob Cohen; Hongbei Wang; Richard J Macchia; Nicholas Karanikolas Journal: Int Braz J Urol Date: 2011 Jan-Feb Impact factor: 1.541
Authors: Joshua Sterling; Zorimar Rivera-Núñez; Hiren V Patel; Nicholas J Farber; Sinae Kim; Kushan D Radadia; Parth K Modi; Sharad Goyal; Rahul Parikh; Robert E Weiss; Isaac Y Kim; Sammy E Elsamra; Thomas L Jang; Eric A Singer Journal: Clin Genitourin Cancer Date: 2020-03-20 Impact factor: 2.872
Authors: Catherine L Callahan; Jonathan N Hofmann; Douglas A Corley; Wei K Zhao; Brian Shuch; Wong-Ho Chow; Mark P Purdue Journal: Cancer Epidemiol Date: 2018-07-18 Impact factor: 2.984
Authors: Onder Kara; Hiury S Andrade; Homayoun Zargar; Oktay Akca; Matthew J Maurice; Peter A Caputo; Daniel Ramirez; Ercan Malkoc; Charles S Modlin; Jihad H Kaouk Journal: J Robot Surg Date: 2016-02-09
Authors: Tracy L Rose; Allison M Deal; Bhavani Krishnan; Matthew E Nielsen; Angela B Smith; William Y Kim; Matthew I Milowsky Journal: Cancer Date: 2016-06-24 Impact factor: 6.860
Authors: Catherine L Callahan; Kendra Schwartz; Douglas A Corley; Julie J Ruterbusch; Wei K Zhao; Brian Shuch; Barry I Graubard; Nathaniel Rothman; Wong-Ho Chow; Debra T Silverman; Mark P Purdue; Jonathan N Hofmann Journal: Cancer Causes Control Date: 2019-11-28 Impact factor: 2.506
Authors: Jie Lin; Shelia H Zahm; Craig D Shriver; Mark Purdue; Katherine A McGlynn; Kangmin Zhu Journal: Cancer Causes Control Date: 2015-05-09 Impact factor: 2.506